Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid

被引:22
作者
Bae, Ja-Seong [1 ]
Choi, Seung Kyu [2 ,3 ]
Jeon, Sora [2 ]
Kim, Yourha [2 ]
Lee, Sohee [1 ]
Lee, Youn Soo [2 ]
Jung, Chan Kwon [2 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul 137701, South Korea
[3] Dankook Univ, Coll Med, Dept Pathol, Cheonan Si 330714, Chungnam, South Korea
基金
新加坡国家研究基金会;
关键词
NEEDLE-ASPIRATION-CYTOLOGY; RAS MUTATIONS; MOLECULAR PATHWAYS; BRAF MUTATIONS; CANCER; CARCINOMA; ONCOGENES; VARIANT; PATTERN; TUMORS;
D O I
10.1155/2014/289834
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Most patients with a preoperative diagnosis of thyroid follicular neoplasm ( FN) undergo diagnostic surgery to determine whether the nodule is benign or malignant. Point mutations at NRAS codon 61 are the most common mutations observed in FN. However, the clinical significance of NRAS mutation remains unclear. Methods. From 2012 to 2013, 123 consecutive patients undergoing thyroidectomy for FN were evaluated prospectively. Molecular analyses for NRAS codon 61 were performed with pyrosequencing. Results. The overall malignancy rate in FN was 48.8% (60/123). Of 123 FNs, 33 (26.8%) were positive for the NRAS mutation. The sensitivity, specificity, positive predictive value, and negative predictive value of a NRAS mutation-positive FN specimen to predict malignancy were 37%, 83%, 67%, and 58%, respectively. Patients with a NRAS-positive FN had a higher malignancy rate in additional thyroid nodules beyond the FN than patients with a NRAS-negative FN. The overall malignancy rate of patients with a NRAS-positive FN was significantly higher than that of patients with a NRAS-negative FN (79% versus 52%; P = 0.008). Conclusions. Determining NRAS mutation status in FN helps to improve the accuracy of thyroid cancer diagnosis and to predict cancer risk in accompanying thyroid nodules.
引用
收藏
页数:7
相关论文
共 26 条
[1]  
An J. H., 2014, CLIN ENDOCRINOLOGY
[2]  
Armstrong MJ, 2014, THYROID
[3]   Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A Synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference [J].
Baloch, Zubair W. ;
LiVolsi, Virginia A. ;
Asa, Syl L. ;
Rosai, Juan ;
Merino, Maria J. ;
Randolph, Gregory ;
Vielh, Philippe ;
DeMay, Richard M. ;
Sidawy, Mary K. ;
Frable, William J. .
DIAGNOSTIC CYTOPATHOLOGY, 2008, 36 (06) :425-437
[4]   The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis [J].
Bongiovanni, Massimo ;
Spitale, Alessandra ;
Faquin, William C. ;
Mazzucchelli, Luca ;
Baloch, Zubair W. .
ACTA CYTOLOGICA, 2012, 56 (04) :333-339
[5]  
BOS JL, 1989, CANCER RES, V49, P4682
[6]   Clinicopathological Features of Rare BRAF Mutations in Korean Thyroid Cancer Patients [J].
Cho, Uiju ;
Oh, Woo Jin ;
Bae, Ja Seong ;
Lee, Sohee ;
Lee, Young Sub ;
Park, Gyeong Sin ;
Lee, Youn Soo ;
Jung, Chan Kwon .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (08) :1054-1060
[7]   Prevalence of Ras mutations in thyroid neoplasia [J].
Esapa, CT ;
Johnson, SJ ;
Kendall-Taylor, P ;
Lennard, TWJ ;
Harris, PE .
CLINICAL ENDOCRINOLOGY, 1999, 50 (04) :529-535
[8]   The Associations Between RAS Mutations and Clinical Characteristics in Follicular Thyroid Tumors: New Insights from a Single Center and a Large Patient Cohort [J].
Fukahori, Michiko ;
Yoshida, Akira ;
Hayashi, Hiroyuki ;
Yoshihara, Mitsuyo ;
Matsukuma, Shoichi ;
Sakuma, Yuji ;
Koizume, Shiro ;
Okamoto, Naoyuki ;
Kondo, Tetsuo ;
Masuda, Munetake ;
Miyagi, Yohei .
THYROID, 2012, 22 (07) :683-689
[9]   BRAF mutations in papillary carcinomas of the thyroid [J].
Fukushima, T ;
Suzuki, S ;
Mashiko, M ;
Ohtake, T ;
Endo, Y ;
Takebayashi, Y ;
Sekikawa, K ;
Hagiwara, K ;
Takenoshita, S .
ONCOGENE, 2003, 22 (41) :6455-6457
[10]   ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer [J].
Garcia-Rostan, G ;
Zhao, HY ;
Camp, RL ;
Pollan, M ;
Herrero, A ;
Pardo, J ;
Ran, W ;
Carcangiu, ML ;
Costa, J ;
Tallini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3226-3235